---
company: SS Innovations International, Inc.
ticker: SSII
form: 8-K
filed: 2026-05-13
accession: 0001213900-26-055468
source: https://www.sec.gov/Archives/edgar/data/1676163/000121390026055468/
---

# SS Innovations International (SSII) earnings release, May 13, 2026

SS Innovations International, Inc. (SSII) · Form 8-K, Item 2.02 · Filed 2026-05-13 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1676163/000121390026055468/)

SS Innovations Reports First Quarter 2026 Financial

Results

Record quarterly revenue driven by strong growth in SSi Mantra installations and procedures

Fort Lauderdale, FL – May 13, 2026 – SS Innovations International, Inc.

(the “Company” or “SS Innovations”)

(Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced unaudited financial results for the three months ended March 31, 2026. The Company also filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, with the Securities and Exchange Commission on May 13, 2026.

First Quarter 2026 Overview

As of March 31, 2026

CEO Commentary

Dr. Sudhir Srivastava, Chairman of the Board and

Chief Executive Officer of SS Innovations, commented, “In the first quarter of 2026 we reported record quarterly revenue of $11.1 million, up 117% year over year, driven by robust growth in SSi Mantra installations and procedures. Strong adoption by hospitals and physicians reflects the SSi Mantra’s cutting-edge surgical robotic technology, differentiated features, user friendliness, training capabilities, and cost efficiency. Among other developments in the quarter, we received regulatory approval for the SSi Mantra for multiple indications in Sri Lanka and Kenya and for telesurgery in Indonesia and the Philippines. We also successfully completed a private placement in March 2026 that provided SS Innovations with approximately $18.6 million in gross proceeds to fuel growth initiatives.”

Dr. Srivastava continued, “Looking ahead, we aim to fortify our position as a leader in the substantial Indian market, expand our global footprint in underserved countries, and secure entry into the United States and European Union markets. We expect the U.S. Food and Drug Administration to complete its review of our 510(k) premarket notification for the SSi Mantra this year. Separately, we continue along the pathway towards a European Union

CE marking certification for the SSi Mantra, which we believe we can also obtain in 2026. We are very excited about the growth runway ahead and remain steadfast in our commitment to democratizing access to advanced surgical robotic care.”

Select Business Highlights in First Quarter

2025

Revenue Breakdown and Summary of Installations

/ Surgeries²

About SS Innovations

SS Innovations International, Inc. (Nasdaq: SSII) develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of robotic surgical procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. Visit the Company’s website at ssinnovations.com or LinkedIn for more information and updates.

About the SSi Mantra

The SSi Mantra surgical robotic system is a user-friendly, modular, multi-arm system with advanced technology features, including: 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, a touch panel monitor for all patient related information display, a virtual real-time image of the robotic patient side arm carts, and the ability for superimposition of 3D models of diagnostic imaging. The optional SSi MantrAsana Tele Surgeon

Console is a portable, compact alternative to the SSi Mantra’s standard surgeon command center that provides equivalent control functionality while enabling enhanced portability, ergonomic flexibility, and telesurgery capability. The SSi Mantra utilizes over 40 different types of robotic endo-surgical instruments to support different specialties, including cardiac surgery, and 5mm instruments for the pediatric population and ENT surgeries. A vision cart provides the table-side team with the same magnified 3D 4K view as the surgeon to provide better safety and efficiency. The SSi Mantra has been clinically validated in India in more than 170 different types of surgical procedures.

Forward Looking Statements

This press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995.

The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,”

“intend,” “may,” “plan,” “project,” “should,” “could,” “seek,”

“designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or SS Innovations’ future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.

Investor Contact:

The Equity Group

Kalle Ahl, CFA

T: (303) 953-9878 kahl@theequitygroup.com

Devin Sullivan, Managing Director

T: (212) 836-9608 dsullivan@theequitygroup.com

Media Contact:

RooneyPartners LLC

Kate Barrette

T: (212) 223-0561 kbarrette@rooneypartners.com³

## Financial statements

### Income Statement (Revenue Breakdown and Summary of Installations / Surgeries)

| | Q1 2025 | Q1 2026 | Variance | Percentage |
|---|---:|---:|---:|---:|
| System sales | 4,502,482 | 9,575,370 | 5,072,888 | 112.7% |
| Instrument sales | 477,208 | 1,151,228 | 674,020 | 141.2% |
| Warranty sales | 122,504 | 357,686 | 235,182 | 192.0% |
| Lease income | 18,416 | 17,082 | -1,334 | -7.2% |
| Total revenue | 5,120,610 | 11,101,366 | 5,980,756 | 116.8% |
| SSi Mantra installations | 15 | 26 | 11 | 73.3% |
| Cumulative installed base1 | 78 | 194 | 116 | 148.7% |
| SSi Mantra surgeries | 787 | 1,859 | 1,072 | 136.2% |
| Cumulative surgeries1 | 3,568 | 9,744 | 6,176 | 173.1% |

### Income Statement (For The Three months ended — (Unaudited))

| | For The Three months ended – March 31, 2026 | For The Three months ended – March 31, 2025 |
|---|---:|---:|
| REVENUES | System sales | 9,575,370 | 4,502,482 |
| REVENUES | Instruments sale | 1,151,228 | 477,208 |
| REVENUES | Warranty sale | 357,686 | 122,504 |
| REVENUES | Lease income | 17,082 | 18,416 |
| REVENUES | Total revenue | 11,101,366 | 5,120,610 |
| REVENUES | Cost of revenue | -5,774,145 | -4,033,402 |
| REVENUES | GROSS PROFIT | 5,327,221 | 1,087,208 |
| OPERATING EXPENSES: | Research & development expense | 995,440 | 1,010,095 |
| OPERATING EXPENSES: | Stock compensation expense | 3,144,315 | 2,379,212 |
| OPERATING EXPENSES: | Depreciation and amortization expense | 323,747 | 208,882 |
| OPERATING EXPENSES: | Selling, general and administrative expense | 4,502,476 | 3,410,872 |
| OPERATING EXPENSES: | TOTAL OPERATING EXPENSES | 8,965,978 | 7,009,061 |
| OPERATING EXPENSES: | Loss from operations | -3,638,757 | -5,921,853 |
| OTHER INCOME (EXPENSE): | Interest Expense | -284,051 | -379,905 |
| OTHER INCOME (EXPENSE): | Interest and other income, net | 491,589 | 620,405 |
| OTHER INCOME (EXPENSE): | TOTAL INCOME, NET | 207,538 | 240,500 |
| OTHER INCOME (EXPENSE): | LOSS BEFORE INCOME TAXES | -3,431,219 | -5,681,353 |
| OTHER INCOME (EXPENSE): | Income tax expense | 151,352 |  |
| OTHER INCOME (EXPENSE): | NET LOSS | -3,582,571 | -5,681,353 |
| CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE LOSS | NET LOSS | -3,582,571 | -5,681,353 |
| OTHER COMPREHENSIVE INCOME (LOSS): | Foreign currency translation loss | -1,557,111 | 6,876 |
| OTHER COMPREHENSIVE INCOME (LOSS): | Retirement Benefit | 4,781 | 15,838 |
| RECLASSIFICATION ADJUSTMENTS: | Retirement Benefit (1) | 3,056 |  |
| RECLASSIFICATION ADJUSTMENTS: | Income tax effects relating to retirement benefit | -1,203 |  |
| RECLASSIFICATION ADJUSTMENTS: | TOTAL OTHER COMPREHENSIVE LOSS | -1,550,477 | 22,714 |
| RECLASSIFICATION ADJUSTMENTS: | TOTAL COMPREHENSIVE LOSS | -5,133,048 | -5,658,639 |

### Balance Sheet ((Unaudited))

| | As of – March 31, 2026 | As of – December 31, 2025 |
|---|---:|---:|
| Current Assets: | Cash and cash equivalents | 15,979,714 | 3,206,406 |
| Current Assets: | Restricted cash | 7,631,336 | 5,937,650 |
| Current Assets: | Accounts receivable, net | 14,054,376 | 12,398,542 |
| Current Assets: | Inventory | 17,066,091 | 17,064,002 |
| Current Assets: | Prepaids and other current assets | 11,530,000 | 10,166,823 |
| Current Assets: | Total Current Assets | 66,261,517 | 48,773,423 |
| Current Assets: | Property, plant, and equipment, net | 8,831,423 | 9,100,546 |
| Current Assets: | Right of use asset, net | 2,499,490 | 2,754,020 |
| Current Assets: | Deferred tax assets, net | 805,750 | 533,727 |
| Current Assets: | Accounts receivable, net-non current | 7,265,911 | 8,566,654 |
| Current Assets: | Restricted cash- non current | 394,630 | 458,964 |
| Current Assets: | Prepaids and other non current assets | 4,488,168 | 4,038,883 |
| Current Assets: | Total Assets | 90,546,889 | 74,226,217 |
| Current Liabilities | Bank overdraft facility | 11,156,147 | 11,442,948 |
| Current Liabilities | Current portion of operating lease liabilities | 576,237 | 579,169 |
| Current Liabilities | Accounts payable | 4,403,170 | 5,127,193 |
| Current Liabilities | Deferred revenue | 3,582,631 | 3,266,686 |
| Current Liabilities | Accrued expenses & other current liabilities | 6,326,818 | 5,825,702 |
| Current Liabilities | Total Current Liabilities | 26,045,003 | 26,241,698 |
| Current Liabilities | Operating lease liabilities, less current portion | 2,086,534 | 2,337,697 |
| Current Liabilities | Deferred Revenue- non current | 7,501,283 | 7,139,807 |
| Current Liabilities | Other non current liabilities | 390,656 | 288,764 |
| Current Liabilities | Total Liabilities | 36,023,476 | 36,007,966 |
| Stockholders’ equity: | Preferred stock, authorized 5,000,000 shares of Series A, Non-Convertible Preferred Stock, $0.0001 par value per share; 1,000 shares issued and outstanding as of March 31, 2026, and December 31, 2025 | 1 | 1 |
| Stockholders’ equity: | Common stock, 250,000,000 shares authorized, $0.0001 par value, 200,131,535 shares and 194,165,141 shares issued and outstanding as of March 31, 2026 and December 31, 2025 respectively | 20,013 | 19,416 |
| Stockholders’ equity: | Accumulated other comprehensive income (loss) | -3,573,137 | -2,022,660 |
| Stockholders’ equity: | Additional paid in capital | 116,549,124 | 95,111,511 |
| Stockholders’ equity: | Capital reserve | 899,917 | 899,917 |
| Stockholders’ equity: | Accumulated deficit | -59,372,505 | -55,789,934 |
| Stockholders’ equity: | Total stockholders’ equity | 54,523,413 | 38,218,251 |
| Stockholders’ equity: | Total liabilities and stockholders’ equity | 90,546,889 | 74,226,217 |

### Cash Flow (For The Three months ended — (Unaudited))

| | For The Three months ended – March 31, 2026 | For The Three months ended – March 31, 2025 |
|---|---:|---:|
| Cash flows from operating activities: | Net loss | -3,582,571 | -5,681,353 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Depreciation and amortization | 323,747 | 208,882 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Operating lease expense | 220,493 | 205,275 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Interest Expense | 43,555 | 155,015 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Interest and other income, net | -415,465 | -140,928 |
